Related Experiment Videos

[Mpl ligand (thrombopoietin) and platelet regulation]

F Wendling1, K Cohen-Solal, N Debili

  • 1INSERM U362, Institut Gustave-Roussy, Villejuif.

Insights

Researchers have identified the key regulator of platelet production, Mpl-L (also known as TPO or MGDF), and cloned its gene. This discovery offers potential new treatments for chemotherapy-induced thrombocytopenia.

Area of Science:

  • Hematology
  • Molecular Biology
  • Oncology

Background:

  • Platelet production is regulated by specific physiological factors.
  • The myeloproliferative leukemia virus (MPLV) provided insights into platelet regulation.
  • MPLV contains the v-mpl oncogene, linked to the c-mpl proto-oncogene.

Purpose of the Study:

  • To isolate and characterize the physiological regulator of platelet production.
  • To clone the gene encoding this regulator.
  • To explore the therapeutic potential of this regulator for thrombocytopenia.

Main Methods:

  • Studies involving the myeloproliferative leukemia virus (MPLV) in mice.
  • Gene cloning of the c-mpl proto-oncogene.
  • Characterization of the Mpl-R cytokine receptor and its ligand, Mpl-L.

Main Results:

  • Isolated the physiological regulator of platelet production after 35 years of research.
  • Cloned the gene for the regulator, identified as Mpl-L (TPO/MGDF).
  • Mpl-R, the receptor for Mpl-L, is expressed on megakaryocyte progenitors, megakaryocytes, and platelets.
  • Mpl-L has a domain similar to erythropoietin responsible for biological activity.
  • Mpl-L potentiates other cytokine actions on hematopoietic lineages.

Conclusions:

  • Mpl-L (TPO/MGDF) is the primary physiological regulator of platelet production.
  • The discovery facilitates understanding of megakaryocytopoiesis and thrombocytopoiesis.
  • Mpl-L/TPO/MGDF shows promise as a therapeutic agent for thrombocytopenia in chemotherapy patients.

Related Concept Videos